INNOVATIVE APPROACH TO NPY Y2 ANTAGONIST DISCOVERY

Information

  • Research Project
  • 2039183
  • ApplicationId
    2039183
  • Core Project Number
    R43NS036474
  • Full Project Number
    1R43NS036474-01
  • Serial Number
    36474
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1997 - 27 years ago
  • Project End Date
    12/31/1997 - 27 years ago
  • Program Officer Name
    KITT, CHERYL A.
  • Budget Start Date
    7/1/1997 - 27 years ago
  • Budget End Date
    12/31/1997 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/30/1997 - 27 years ago

INNOVATIVE APPROACH TO NPY Y2 ANTAGONIST DISCOVERY

The objective of this proposal is the discovery of antagonists for the neuropeptide Y (NPY) Y2 subtype of receptor to further define the role of this receptor in mediating the diverse pharmacological properties of NPY. The authors propose and present data in support of a computational approach to drug lead discovery, which involves I) constructing two virtual libraries (VL1 and VL2) (computer models of compounds) from proprietary low affinity Y2 antagonist drugs and structural motifs of known G protein-coupled receptor ligands, and ii) docking molecules which comprise VL1 and VL2 in a Y2 receptor (computer) model (virtual screening) to select compounds which bind the Y2 receptor with high affinity. Validation of the method will be achieved via chemical synthesis and pharmacological evaluation of the molecules which comprise VL1 and VL2 in NPY Y binding and functional assays. Selectivity of preferred compounds will be assessed against Y1, Y4, and Y5 receptors. The authors suggest that their preliminary studies have demonstrated the feasibility of this approach in that they have successfully identified a known Y1 selective antagonist (BIBP3226) as a positive (hit) from virtual screening of a 343 member library against a Y1 receptor model. Phase II goals include the refinement of the computational method and antagonist lead drugs, their exploitation in Y2 target validation and the discovery of Y2 agonists.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    SYNAPTIC PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    PARAMUS
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07652
  • Organization District
    UNITED STATES